Senolytic treatments applied to osteoarthritis: a step towards the end of orthopedic surgery?
Editorial

Senolytic treatments applied to osteoarthritis: a step towards the end of orthopedic surgery?

Olivier Malaise1,2*, Yassin Tachikart1*, Jean-Marc Brondello1

1IRMB, INSERM, Univ Montpellier, Montpellier, France; 2GIGA Research, CHU of Liège & University of Liege, Liege, Belgium

*These authors contributed equally to this work.

Correspondence to: Dr. Jean-Marc Brondello, Ing-PhD, HDR. INSERM U1183, Institute for Regenerative Medecine and Biotherapies, CHU St Eloi 80 av A. Fliche, 34298 Montpellier cedex 05, France. Email: jean-marc.brondello@inserm.fr.

Provenance: This is a Guest Editorial commissioned by Section Editor Deng Zhantao, PhD (Department of Orthopedics, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, China).

Comment on: Jeon OH, Kim C, Laberge RM, et al. Local clearance of senescent cells attenuates the development of post-traumatic osteoarthritis and creates a pro-regenerative environment. Nat Med 2017;23:775-81.


Received: 12 September 2017; Accepted: 26 September 2017; Published: 31 October 2017.

doi: 10.21037/amj.2017.10.01


Osteoarthritis (OA) is the most common chronic degenerative disease of the joint for which more than 1/3 of the population after 60 years old have radiographic signs for knee OA (1). OA has pejorative consequences on quality of life and working abilities, leads to a social isolation in elderly and has a significant impact on the public health costs.

To date, no validated curative medical treatments for OA are available. New “symptomatic slow-acting drugs” such as glucosamine and visco-supplementation with hyaluronic acid are used in OA, but they still lack evidence for efficiency on long-term structural articular remodeling (2,3). Therefore, OA still shows a huge unmet need while symptomatic painkiller treatments and physiotherapy remain the main alternatives before prosthetic surgical joint replacement.

A range of clinical risk factors favors OA development. Next to local risk factors with overweight and life-driven repetitive or acute mechanical stresses, there are also systemic risk factors. Among them, the first one is ageing. Indeed, knee OA rate increases continuously with age, with the highest relative risk between 70–75 years old (4).

For long, OA was only considered as a degenerative disease of the cartilage per se. However, other joint structures play roles in OA etiology. Synovial membrane, that acquires inflammatory hypertrophic phenotype, contributes to symptoms severity, osteophytes formation and even articular erosion (5). Furthermore, remodeling of the subchondral bone is not only a consequence but also rather an active component of the disease, generating pain and articular loss of function (6). Thus, recent data teach us that OA is more a global and heterogeneous joint disease with both inflammatory and metabolic components. A new emerging theory linking age-related OA pathology and inflammation reveals the role of cellular senescence in OA onset, as recently demonstrated by Jeon et al. in Nature Medicine (7). Cellular senescence is a permanent cell proliferative arrest induced by intrinsic signals including telomere erosion but also extrinsic inappropriate stimuli such as free radicals or chronic exposure to inflammatory cytokines (8). Senescence is associated with dramatic changes in cell morphology, metabolism, epigenetic and genes expression (8). Several cyclin-dependent kinase inhibitors including the hallmark p16INK4a participate to senescence onset (9). Senescence program will thus trigger changes in cell functions pushing toward a terminal differentiated phenotype (10) meanwhile influencing tissue homeostasis through the establishment of one specific secretory phenotype so-called SASP for “senescence-associated secretory phenotype” (11).

Cellular senescence features on chondrocytes have been found for years in articular cartilage isolated from OA patients compared to matched-age non-OA donors (12). Indeed OA chondrocytes harbor premature telomeric shortening (12), DNA damage accumulation (13) meanwhile an increase in p16ink4a expression and p16ink4a-dependent MMP-1 and MMP-13 metallo-proteases secretion (10). All these events seem to be deleterious for cartilage maintenance although still lack a causal demonstration for the role of cellular senescence in OA development

In the recent Nature Medicine volume, Jeon et al. demonstrate for the first time a clear correlation between OA onset and accumulation of senescent cells in joint of surgically induced OA murine models. They took advantage of two transgenic murine models allowing non-invasive detection of senescent cells and their specific elimination after pharmacological challenges. The first model, p16-3MR, consists in mice driving a luciferase fused with a truncated form of herpes simplex virus 1 thymidine kinase under the control of p16INK4a promoter. The second one INK-ATTAC mouse consists in p16INK4a-driven expression of luciferase and caspase 8 suicide gene. Both models allow monitoring of p16INK4a-positive senescent cells through luciferine delivery and their selective elimination in response to ganciclovir or AP20187 respectively. Jeon et al. first monitored the presence of articular senescent cells in 2-month-old p16-3MR mice following OA induction after anterior cruciate ligament transection. Using intra-articular luciferase injection, they could reveal a significant pick in senescent cells accumulation at 14 days post-surgery. Following immunohistochemistry staining, they detected p16INK4a-positive senescent cells in activated synovium and in the superficial cartilage zones.

To determine whether articular p16INK4a senescent cells are responsible for OA onset, they elegantly eliminate these cells in the knee of animals that underwent surgery by intra-articular injections of ganciclovir. Local elimination of articular senescent cells was associated with less cartilage degradation, less cartilage expression of inflammatory markers such as IL-1β and less hypertrophic catabolic markers such as MMP-13. One of major interest of these studies was to find a higher expression level for two pro-chondrogenic markers namely collagen type IIB and aggrecan in treated mice. To bring further convincing argument, the authors used the second transgenic model to study spontaneous OA onset in older mice. Remarkably, treatment by AP20187, delivered in 12-months-old INK-ATTAC mice up to their natural death, maintains healthy cartilage and therefore reduces the appearance of spontaneous age-related OA signs.

Senescent cells are characterized by their resistance to apoptotic signals through up-regulation of anti-apoptotic BCL2-BCLX pathway (14). Several teams in the world have recently validated drugs that could specifically trigger cell death on senescent cells by targeting this anti-apoptotic axis. Thus, several of these so-called senolytic drugs, including UBX0101 (also known as ABT263), have already been validated as anti-senescent treatment in mice suffering from different age-related diseases (15): for instance, senolytics improved cardiac function in old mice (16), prevented osteoporosis (17), delayed loss of intervertebral disk proteoglycans in progeric Ercc-/Δ mice (16), reversed irradiation-induced pulmonary fibrosis (18) and depleted senescent hematopoietic and muscle stem cells in old mice (19).

To test the efficacy of such senolytic drugs as new innovative OA treatment, Jeon et al. performed 6 intra-articular injections (every 2 days) of UBX0101 in 2-month-old mice, 14 days post-surgery when articular senescence was the highest. Results were impressive: UBX0101 significantly reduced p16INK4a senescent cells induced by surgery, but also cartilage degradation and OA-related pain after 28 days. Moreover, UBX0101 treatment reduced MMP-13, IL-6 and IL-1β expression in cartilage while promoting neo-cartilage formation, with an increase in collagen type II and aggrecan production. The authors concluded that UBX0101, by eliminating articular senescent cells, reduced experimental post-traumatic OA symptoms and disease severity in mice. Furthermore, UBX0101 stimulated new cartilage formation.

To translate these results from murine models to human OA patients, Jeon et al. offer convincing in vitro evidences. Using monolayer and 3D culture of human chondrocytes isolated from late-stage OA cartilage obtained after arthroplasty surgery, they showed that UBX0101 treatment reduced the expression of senescence- and OA-associated genes and even increased the proliferation rate of the remaining chondrocytes, indicating new cartilage growth. By eliminating senescent cells, UBX0101 not only removes a causative actor in OA process, but also restores a pro-chondrogenic environment. Thus, the authors add a new and promising category of drugs in the therapeutic arsenal of all physicians involving in OA management.

As for every new major step in medicine, several questions should be solved before UBX0101 human application in OA. First, UBX0101 is already used to treat cancer in phase I/II trials (20) and side effects, e.g., thrombocytopenia, have been described (21). The author’s choice to inject locally the drug is reassuring: the systemic exposure in this case was very low (only 3,3% of the intra-articular dose) in mice. We can hypothesize that the systemic toxicity will be negligible in intra-articular treated patients. Nevertheless, the patient’s fear for such molecules could become a problem. To circumvent this potential limitation, several other molecules less toxic (e.g., the flavonoid quercetin) have been screened for senolytic properties (16) and could be proposed as an alternative.

In daily practice, patients usually present late-stage disease with severe cartilage lesions. Jeon et al. also answered this question by injecting UBX0101 in young mice not only 14 but also 42 days after OA induction, when cartilage degradation was higher. They still observed an increase in cartilage staining and chondrogenic genes expression, suggesting that UBX0101 was also efficient in later-stage disease. However, UBX0101 was not able to reduce abnormal subchondral bone remodeling and osteophyte formation in these mouse models. The authors suggest that the local injection did not allow the drug to reach the bone. This could be a clinical limitation, as subchondral bone modifications are able to modulate OA severity (6).

Lastly, OA prevalence increases with ageing (4). To extrapolate their models to the elderly, 19 months old mice were used. The systemic removal of p16INK4a senescent cells markedly reduced the spontaneous age-related cartilage degradation, confirming that targeting senescence was also promising in older patients. However, in this case, intra-articular injection of UBX0101 alone had no impact on cartilage degradation and did not enhance chondrogenic genes expression in old mice. Thus, as discussed, intra-articular injection in aged patients would probably not be enough and a systemic treatment should be considered. The risk-benefit ratio of systemic administration of anti-cancer therapies to delay OA onset must therefore be carefully investigated.

In conclusion, evidences are accumulating that link cellular senescence features and numerous age-related pathologies including osteoporosis, sarcopenia or heart hypertrophy affecting elderly (15). Demonstrating that senescent cells are participating to OA onset is the major finding of this study paving thus the way to very promising innovative senolytic drugs-based treatments for OA. Nevertheless, one has to keep in mind that cellular senescence is also a physiological positive process implicated in wound healing, tumor suppression, immune and anti-viral responses, among others (22,23). We thus lack the perspectives on long-term effects and safety for senolytic treatments on human health. So the road is still long before celebrating the end of orthopedic surgery to treat OA.


Acknowledgements

This work was supported by INSERM and the french national aging consoritum: Age-Med. Y Tachikart is a Pharmacy resident at CHU Montpellier, France. O Malaise is funded by CHU of Liege, University of Liege, Belgium.


Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.


References

  1. Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008;58:26-35. [Crossref] [PubMed]
  2. Runhaar J, Rozendaal RM, Middelkoop MV, et al. Subgroup analyses of the effectiveness of oral glucosamine for knee and hip osteoarthritis: a systematic review and individual patient data meta-analysis from the OA trial bank. Ann Rheum Dis 2017. [Epub ahead of print]. [Crossref] [PubMed]
  3. McAlindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage 2014;22:363-88. [Crossref] [PubMed]
  4. Prieto-Alhambra D, Judge A, Javaid MK, et al. Incidence and risk factors for clinically diagnosed knee, hip and hand osteoarthritis: influences of age, gender and osteoarthritis affecting other joints. Ann Rheum Dis 2014;73:1659-64. [Crossref] [PubMed]
  5. Scanzello CR, Goldring SR. The role of synovitis in osteoarthritis pathogenesis. Bone 2012;51:249-57. [Crossref] [PubMed]
  6. Yu D, Xu J, Liu F, et al. Subchondral bone changes and the impacts on joint pain and articular cartilage degeneration in osteoarthritis. Clin Exp Rheumatol 2016;34:929-34. [PubMed]
  7. Jeon OH, Kim C, Laberge RM, et al. Local clearance of senescent cells attenuates the development of post-traumatic osteoarthritis and creates a pro-regenerative environment. Nat Med 2017;23:775-81. [Crossref] [PubMed]
  8. Collado M, Blasco MA, Serrano M. Cellular senescence in cancer and aging. Cell 2007;130:223-33. [Crossref] [PubMed]
  9. Krishnamurthy J, Torrice C, Ramsey MR, et al. Ink4a/Arf expression is a biomarker of aging. J Clin Invest 2004;114:1299-307. [Crossref] [PubMed]
  10. Philipot D, Guerit D, Platano D, et al. p16INK4a and its regulator miR-24 link senescence and chondrocyte terminal differentiation-associated matrix remodeling in osteoarthritis. Arthritis Res Ther 2014;16:R58. [Crossref] [PubMed]
  11. Coppe JP, Patil CK, Rodier F, et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 2008;6:2853-68. [Crossref] [PubMed]
  12. Price JS, Waters JG, Darrah C, et al. The role of chondrocyte senescence in osteoarthritis. Aging Cell 2002;1:57-65. [Crossref] [PubMed]
  13. Loeser RF, Collins JA, Diekman BO. Ageing and the pathogenesis of osteoarthritis. Nat Rev Rheumatol 2016;12:412-20. [Crossref] [PubMed]
  14. Wang E.. Senescent human fibroblasts resist programmed cell death, and failure to suppress bcl2 is involved. Cancer Res 1995;55:2284-92. [PubMed]
  15. Childs BG, Gluscevic M, Baker DJ, et al. Senescent cells: an emerging target for diseases of ageing. Nat Rev Drug Discov 2017;16:718-35. [Crossref] [PubMed]
  16. Zhu Y, Tchkonia T, Pirtskhalava T, et al. The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell 2015;14:644-58. [Crossref] [PubMed]
  17. Farr JN, Xu M, Weivoda MM, et al. Targeting cellular senescence prevents age-related bone loss in mice. Nat Med 2017;23:1072-9. [Crossref] [PubMed]
  18. Pan J, Li D, Xu Y, et al. Inhibition of Bcl-2/xl With ABT-263 selectively kills senescent type II pneumocytes and reverses persistent pulmonary fibrosis induced by ionizing radiation in mice. Int J Radiat Oncol Biol Phys 2017;99:353-61. [Crossref] [PubMed]
  19. Chang J, Wang Y, Shao L, et al. Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nat Med 2016;22:78-83. [Crossref] [PubMed]
  20. Delbridge AR, Grabow S, Strasser A, et al. Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies. Nat Rev Cancer 2016;16:99-109. [Crossref] [PubMed]
  21. Kaefer A, Yang J, Noertersheuser P, et al. Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of navitoclax (ABT-263) induced thrombocytopenia. Cancer Chemother Pharmacol 2014;74:593-602. [Crossref] [PubMed]
  22. He S, Sharpless NE. Senescence in Health and Disease. Cell 2017;169:1000-11. [Crossref] [PubMed]
  23. Vicente R, Mausset-Bonnefont AL, Jorgensen C, et al. Cellular senescence impact on immune cell fate and function. Aging Cell 2016;15:400-6. [Crossref] [PubMed]
doi: 10.21037/amj.2017.10.01
Cite this article as: Malaise O, Tachikart Y, Brondello JM. Senolytic treatments applied to osteoarthritis: a step towards the end of orthopedic surgery? AME Med J 2017;2:161.

Refbacks

  • There are currently no refbacks.